A Multicenter Study of Ibrutinib Resistance Development and Intervention With Venetoclax (Phase II)
Latest Information Update: 11 Nov 2021
At a glance
- Drugs Ibrutinib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 29 Oct 2021 Status changed from recruiting to withdrawn prior to enrolment.
- 11 Mar 2020 Status changed from not yet recruiting to recruiting.
- 12 Dec 2019 Planned number of patients changed from 36 to 160.